Long-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics.

Abstract

BACKGROUND:

Despite the emergence of multiple biologic drug options for psoriasis, unmet treatment needs remain. Biologic therapies can vary in their effectiveness and adverse events, and many patients experience a loss of treatment effect over time. After lack of response, treatment may be switched to a biologic with a different mechanism of action. Brodalumab, a human interleukin-17 (IL-17) receptor A antagonist, is approved for the treatment of adult patients with moderate-to-severe psoriasis with inadequate response or loss of response to prior systemic therapies. Because brodalumab targets the IL-17 receptor instead of the ligand itself, it not only targets a broader set of IL-17 isoforms but also may be effective in patients who received prior IL-17 inhibitors or failed to respond to anti–IL-17 treatment. This is supported by long-term evidence from clinical trials and real-world studies of patients receiving brodalumab who were previously treated with IL-17 inhibitors. Additionally, brodalumab produces reliable treatment effects after use of biologics with other mechanisms of action, such as tumor necrosis factor α and IL-12/IL-23 inhibitors, as well as after the use of multiple biologic therapies. For patients with psoriasis with inadequate response to one or more biologic therapies, brodalumab is an option that has the ability to lead to long-term skin clearance. J Drugs Dermatol. 2022;21(3):364-370. doi:10.36849/JDD.6743.

• Authors: Mark Lebwohl, Alan Menter, Edward Lain, George Han, Abby Jacobson
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 21 Issue 4 Pg. 354-370 (04 01 2022) ISSN: 1545-9616 [Print] United States
• PMID: 35389586 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Biological Products
• Interleukin-17
• Receptors, Interleukin-17
• brodalumab

Topics

• Adult
• Antibodies, Monoclonal (adverse effects)
• Antibodies, Monoclonal, Humanized
• Biological Products (adverse effects)
• Humans
• Interleukin-17
• Psoriasis (chemically induced, diagnosis, drug therapy)
• Receptors, Interleukin-17
• Severity of Illness Index
• Treatment Outcome